- 期刊
Therapeutic Effect of Arsenic Trioxide Containing Lotion in a Human Bladder Carcinoma Xenograft Model
三氧化二砷外用劑對異體移植模式人類膀胱癌細胞的治療效果
摘要
BACKGROUND: Patients with metastatic carcinoma develop cutaneous metastases in about 10% of cases. These skin metastatic lesions are usually treated by radiation therapy and/or chemotherapy with disappointing results. In this study we used human bladder carcinoma xenograft nuice as a model to investigate whether arsenic trioxide lotion has an anti-tumor effect on skin metastases of human solid tumor cells. MATERIALS AND METHODS: Female BALB/c-Hfbllnu mice received subcutaneous injection to the left flanks on day 0 with 2×10^6 viable HTB-9 tumor cells. When the mean tumor size reached 7-8mm at the 19(superscript th) day, the mice were randomly divided into three groups of six mice. The first group was treated with the lotion containing no arsenic trioxide and served as the control group. The second group were given artificial wounds on tumors which were then treated with arsenic trioxide lotion. The third group was treated with the arsenic trioxide lotion on tumors. The treatment schedule was three times a week. The total dose of each treatment was 0.14gm lotion (containing 0.0462mg arsenic trioxide), which was applied to the skin over each visible tumor. RESULTS: There was a significant difference (P＜0.05) in tumor growth between group 1 and group 2, and between group 1 and group 3 beginning from the 35(superscript th) day after treatment, but there was no significant difference between group 2 and group 3. Arsenic trioxide lotion treatment delayed the growth of the subcutaneous bladder carcinoma regardless of whether the tumor was covered by skin or artificially wounded. CONCLUSION: The results of this study suggest that arsenic trioxide lotion is a worthy candidate for clinical trials.
關鍵字
無資料並列摘要
BACKGROUND: Patients with metastatic carcinoma develop cutaneous metastases in about 10% of cases. These skin metastatic lesions are usually treated by radiation therapy and/or chemotherapy with disappointing results. In this study we used human bladder carcinoma xenograft nuice as a model to investigate whether arsenic trioxide lotion has an anti-tumor effect on skin metastases of human solid tumor cells. MATERIALS AND METHODS: Female BALB/c-Hfbllnu mice received subcutaneous injection to the left flanks on day 0 with 2×10^6 viable HTB-9 tumor cells. When the mean tumor size reached 7-8mm at the 19(superscript th) day, the mice were randomly divided into three groups of six mice. The first group was treated with the lotion containing no arsenic trioxide and served as the control group. The second group were given artificial wounds on tumors which were then treated with arsenic trioxide lotion. The third group was treated with the arsenic trioxide lotion on tumors. The treatment schedule was three times a week. The total dose of each treatment was 0.14gm lotion (containing 0.0462mg arsenic trioxide), which was applied to the skin over each visible tumor. RESULTS: There was a significant difference (P＜0.05) in tumor growth between group 1 and group 2, and between group 1 and group 3 beginning from the 35(superscript th) day after treatment, but there was no significant difference between group 2 and group 3. Arsenic trioxide lotion treatment delayed the growth of the subcutaneous bladder carcinoma regardless of whether the tumor was covered by skin or artificially wounded. CONCLUSION: The results of this study suggest that arsenic trioxide lotion is a worthy candidate for clinical trials.